| CAS NO: | 10537-47-0 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Cas No. | 10537-47-0 |
| 别名 | 酪氨酸磷酸化抑制剂A9,Tyrphostin 9; Malonoben |
| 化学名 | 2-[(3,5-ditert-butyl-4-hydroxyphenyl)methylidene]propanedinitrile |
| Canonical SMILES | CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)C=C(C#N)C#N |
| 分子式 | C18H22N2O |
| 分子量 | 282.38 |
| 溶解度 | ≥ 14.1mg/mL in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Tyrphostin 9 is an inhibitor of PDGFR with IC50 value of ~2.5μM [1]. Tyrphostin 9 is generated as specific inhibitor of PDGFR in 1991. It also has inhibitory effect on the proliferation of SMC. Tyrphostin 9 potently inhibits the PDGF-dependent SMC proliferation with IC50 value of 40nM and inhibits the PDGF-dependent autophosphorylation of PDGFR with IC50 value of ~2.5μM. Besides that, Tyrphostin 9 also affects the phosphorylation of PLCγ (IC50 value of about 2.5μM) and the PDGF-dependent c-fos expression. Moreover, Tyrphostin 9 is found to be an inhibitor of EGFR with IC50 value of 460μM [1, 2]. In the rat carotid artery injury model, treatment of Tyrphostin 9 significantly reduces neointimal hyperplasia through inhibiting the tyrosine phosphorylation in injured arteries [1]. References: |
m.cnreagent.com